Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Can-Fite BioPharma has successfully completed a preclinical trial with CF101 in the treatment of uveitis. Can-Fite also signed an M-CRADA with the National Institute of Health to expand the preclinical studies and further explore the efficacy of CF101 in the treatment of uveitis.
Subscribe to our email newsletter
This preliminary trial was conducted at the National Eye Institute (NEI), which is part of the US National Institute of Health (NIH). The trial, which examined the effect of CF101 in a preclinical animal model, demonstrated that the drug was able to significantly reduce ocular disease symptoms via a definitive immunological mechanism of action.
Pnina Fishman, CEO of Can-Fite, said: “The current standard of care for patients with uveitis is steroids and general immunosuppression therapy. The lack of specific drugs for the treatment of this condition creates a need for novel targeted therapies such as the products Can-Fite develops.”